IgA Nephropathy clinical trials at UCSF

• A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

  open to eligible people ages 18-65

  The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). These patients are at high risk for progression of kidney disease, which can result in end-stage renal failure.

  San Francisco, California and other locations

Last updated: April 16, 2021